What is Wedbush’s Estimate for Immunome FY2024 Earnings?

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at Wedbush increased their FY2024 earnings per share (EPS) estimates for Immunome in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($2.11) per share for the year, up from their prior forecast of ($2.23). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.13) per share. Wedbush also issued estimates for Immunome’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($2.70) EPS and FY2027 earnings at ($2.11) EPS.

IMNM has been the subject of a number of other reports. Stephens started coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Piper Sandler reduced their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $28.83.

Immunome Trading Down 4.7 %

Shares of NASDAQ:IMNM opened at $9.44 on Monday. Immunome has a 1-year low of $6.93 and a 1-year high of $30.96. The stock has a market capitalization of $588.93 million, a P/E ratio of -1.16 and a beta of 1.82. The business has a 50-day moving average price of $13.02 and a two-hundred day moving average price of $13.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Quest Partners LLC bought a new stake in shares of Immunome during the second quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Immunome during the 2nd quarter worth about $97,000. Arizona State Retirement System raised its stake in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares during the period. Institutional investors own 44.58% of the company’s stock.

Insider Activity at Immunome

In related news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares in the company, valued at approximately $760,090.76. The trade was a 23.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.60% of the stock is owned by corporate insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.